Elitecon International Ltd Q2FY26 – From Zero Revenue to ₹505 Crore Sales and a ₹387 Cr GST Show Cause Notice. Tobacco, Drama & 4,000% Stock Surge – This Quarter’s Spiciest Roll-Up Story.
1. At a Glance
Welcome to the wildest comeback in Dalal Street history — Elitecon International Ltd (BSE: 539533), once a forgotten tobacco trader, now a ₹26,000 crore market cap “turnaround” rocket ship. From a mere ₹5 in 2023 to ₹423 in 2025 before cooling to ₹163 — that’s not a multibagger, that’s a NASA trajectory with nicotine propulsion.
The latest Q2FY26 (September 2025) results scream resurrection with side drama: Revenue at ₹505 crore (up 538% YoY), PAT at ₹20.2 crore (up 129% YoY), but hey — the taxman wants his share too, courtesy a ₹387.43 crore GST show cause notice. Because what’s an Indian turnaround without some regulatory masala?
At ₹163 per share, the stock trades at a jaw-dropping P/E of 438x and a price-to-book of 161x. ROE is a bonkers 124%, ROCE at 33%, but dividend yield — the corporate equivalent of dry tobacco — sits at 0.00%. Promoters hold 59.4%, FIIs 38%, and the public, well, just watches from 2.3%.
From “no revenue and losses” to “quarterly ₹505 crore sales,” Elitecon’s transformation is either a masterstroke of business pivot or the most poetic financial miracle since Harshad’s days. Buckle up.
2. Introduction
Let’s rewind. Once upon a time in 1987, a humble tobacco company was born — Elitecon International Ltd, best known for its dreams rather than numbers. For years, the balance sheet was quieter than a smoker trying to hide from his wife. Then, somewhere around FY23–24, the script flipped.
Suddenly, the company started spewing announcements faster than cigarette smoke rings: acquisitions, preferential issues, QIPs, overseas subsidiaries, convertible warrants — the whole Bollywood-style corporate comeback. They bought Pandokhar Food LLP, Golden Cryo Pvt Ltd, formed a UAE subsidiary, and now even want to buy FMCG companies. Because why stick to one addictive product when you can own the entire shelf of bad habits?
From a ₹5 penny stock to ₹423 in under two years — it’s the sort of move that makes small investors feel like prophets… until gravity reminds them that valuation also exists. The 3-month return? -34%. The 6-month? +353%. Truly the stock market’s version of bipolar disorder.
The irony? Despite 403% profit CAGR over 5 years, Elitecon still doesn’t pay dividends. Maybe they believe in reinvesting… or repackaging. Either way, FY26 is shaping up as a test of whether this rebranding is sustainable — or just a puff of smoke.
3. Business Model – WTF Do They Even Do?
So what does Elitecon actually do besides make investors faint?
Well, officially, they manufacture and trade tobacco-based products — from smoking mixtures, cigarettes, and flavored molasses to khaini, zarda, and even something called “Yummy Filter Khaini.” (Yes, they really named it Yummy; only in India can carcinogens be branded appetizingly.)
But the real twist lies in their expansion binge. Elitecon has now entered international markets — UAE, Singapore, Hong Kong, UK, and parts of Europe. They even plan to diversify into matchsticks, pipes, and snuff grinders — basically every 19th-century smoker’s starter pack.
Recent acquisitions show they’re also venturing into food, cryogenics, and FMCG. From “smoke to snacks,” the diversification logic seems to be: “If it sells, we’ll buy it.” Their UAE subsidiary hints at ambitions to globalize the brand, and given the Indian tobacco industry’s regulation-heavy landscape, offshore expansion might be a clever escape route… or a smoke screen.
So yes — they sell tobacco, dream FMCG, and occasionally issue warrants worth ₹158 crore to themselves. Sounds messy? That’s because it is. But in the land of small caps, chaos is a business model.
4. Financials Overview
Metric (₹ Cr)
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
505
79
199
+538%
+154%
EBITDA
22
8
21
+175%
+4.8%
PAT
20.2
8.8
20.0
+129%
+1.0%
EPS (₹)
0.13
0.07
0.13
+86%
0%
Annualised EPS: ₹0.52 → P/E = 163 / 0.52 = ~313x (but Screener’s showing 438x, depending on TTM EPS of ₹5.8). Anyway, whichever way you slice it — this stock is priced like it sells oxygen, not tobacco.
Commentary: Revenue growth is extraordinary — from ₹79 crore to ₹505 crore in a year. EBITDA margins remain thin at 4–7%, but profitability consistency is new territory for Elitecon. However, when you mix a ₹20 crore PAT with a ₹26,000 crore market cap, it’s like buying a ₹10 chai for ₹2,000 because it’s in a fancy cup.
5. Valuation Discussion – Fair Value Range (Educational Only)
Let’s pull out the calculator before the auditors faint.
